Recent Advancement in Management of H. Pylori Induced PUD

Helicobacter pylori (H. pylori) infection is a significant global health issue, affecting nearly half of the world’s population. This bacterium colonizes the stomach lining and is linked to various gastrointestinal disorders, including chronic gastritis, peptic ulcers, and gastric cancer. The standard treatment typically involves a combination of antibiotics and proton pump inhibitors (PPIs); however, the growing prevalence of antibiotic-resistant strains has made treatment more challenging. Advances in diagnostic techniques now include non-invasive testing methods and serological biomarkers. While conventional antibiotic and PPI therapy remains the primary approach, there is increasing interest in alternative treatments such as botanical extracts, natural compounds, and traditional medicine. Researchers have also investigated the role of probiotics, phage therapy, and emerging antibiotics like rifabutin and furazolidone in combating H. pylori. Additionally, artificial intelligence (AI) has shown potential in enhancing diagnosis and treatment strategies. AI-powered screening has helped identify novel botanical compounds with anti-H. pylori properties, offering new therapeutic possibilities. Furthermore, AI-driven methods can enhance diagnostic precision and treatment efficacy. Although these alternative approaches appear promising, further studies are essential to determine their effectiveness, safety, and optimal dosages. Innovative treatments, including phage therapy and next-generation antibiotics, may provide viable solutions to combat antimicrobial resistance in H. pylori infections.